The table below shows Amneal Pharmaceuticals, Inc.'s cash flow statement line items across its last 6 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
Line item
FY 2025
FY 2024
FY 2023
FY 2022
FY 2021
FY 2020
Operating cash flow
$339.99M
$295.10M
$345.58M
$65.10M
$241.82M
$379.00M
Capital expenditure
$70.06M
$51.92M
$43.22M
$46.41M
$47.73M
$56.45M
Investing cash flow
-$112.26M
-$63.00M
-$69.19M
-$174.31M
-$194.18M
-$317.55M
Dividends paid
-
-
-
-
-
AMRX operating cash flow (10-K history)
Amneal Pharmaceuticals, Inc. reported operating cash flow of $339.99M for fiscal year 2025. That is up 15.2% from $295.10M in fiscal 2024. Over the 10 fiscal years shown, operating cash flow grew from $115.06M (FY 2016) to $339.99M. Figures come from the company's audited annual reports as filed with the SEC.
